# Rapha Capital Management

Rapha Capital Management is a Private Equity based in Surfside, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Surfside, United States
- **Region:** North America
- **Address:** 9511 Collins Avenue, #1403, Surfside, FL 33154, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** raphacap.com
- **LinkedIn:** https://www.linkedin.com/company/rapha-capital-management-llc

## Regulatory record

- **Reports private funds:** No

## About

Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities | We use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities

## Sectors

- Biotech
- Digital Health
- Medical Devices
- Longevity

## People

- Kevin Slawin — Founder and Managing Partner

## Questions

### How does Rapha Capital source proprietary deal flow?

Rapha Capital co-invests in and operates out of K2 Biolabs, a Houston-based biotech co-working facility co-founded by Kevin Slawin. This physical infrastructure gives Rapha Capital early visibility into startup formation, enabling it to seed companies before traditional venture capital processes engage. Slawin's operating companies — Ponce Therapeutics and DELiver Therapeutics — also generate pipeline through internal R&D programs.

### Is Rapha Capital structured as a venture firm or an incubator?

Rapha Capital operates as a private equity firm running 13 managed investment entities and multiple fund vehicles, including Rapha Capital BioVentures Fund I and Rapha Capital PE Life Sciences Fund VI. Functionally, it blends venture investing with a biotech studio model because Slawin personally co-founds and incubates several portfolio companies through K2 Biolabs.

### What investment stages does Rapha Capital typically target?

Rapha Capital invests primarily at the seed and early institutional stages. Companies like PrintBio and Phoenix SENOLYTIX entered the portfolio before or during preclinical development, and Slawin's thesis emphasizes identifying disruptive biotechnologies before they surface in broader venture pipelines.

## Related profiles

- [Rannapo Partners](https://altss.com/profile/rannapo-partners)
- [Rapid Scale](https://altss.com/profile/rapid-scale)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/rapha-capital-management

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology